Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545
Discontinued
Reference number: GID-TA10418
Following on from information provided to NICE by the company in July 2020 the appraisal of Pembrolizumab with chemotherapy for treating advanced or metastatic urothelial cancer [ID1545] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.